|General Partners - Scientific Advisors - Fund Advisors|
Mike Pape, PhD
In 1998, Dr. Pape left Parke-Davis to co-found Esperion Therapeutics, a publicly-traded biopharmaceutical company that discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. At Esperion, he led a variety of initiatives involving aspects of both science and business while holding several executive positions. He now serves as Vice President of Cellular and Molecular Biology. Esperion sold to Pfizer in 2004 for $1.3 billion.
Prior to Esperion, Mike held research positions in the Department of Metabolic Diseases at The Upjohn Company (now Pfizer) in Kalamazoo, Michigan and in the Departments of Atherosclerosis and Molecular Biology at Parke-Davis Pharmaceutical Research (now Pfizer) in Ann Arbor, Michigan. Dr. Pape and his research teams have published numerous articles detailing the biochemistry of atherosclerosis, diabetes, and obesity with an emphasis on the mechanism by which drugs can alter these diseases.
He is an Adjunct Assistant Professor in the Department of Biological Chemistry at the University of Michigan Medical School. He serves on the Board of Directors of the Michigan Biosciences Industry Association (MichBio, a statewide organization promoting biosciences in Michigan) and ProNAi Board. Dr. Pape has spoken to numerous audiences of current and would-be life sciences entrepreneurs describing the progression of Esperion from a start-up to an emerging biopharmaceutical company.
Dr. Pape received his B.S. degree in Microbiology from the University of Michigan and his Ph.D. in Biochemistry from Purdue University.
Ken Seltzer, MD
Ken Seltzer has twenty years experience with healthcare service, biotechnology, medical device and pharmaceutical companies. His business experience includes senior management positions in both an entrepreneurial environment as well as the large corporate environment of Pharmacia, which had 60,000 employees globally before it merged with Pfizer . Ken was the founder and CEO of INC Research, the third company he founded . Ken successfully raised $40 million dollars in Venture Capital money from four blue chip Venture funds, building INC Research into the largest CRO in the world focused on CNS/Pain clinical trials in phases I to IV. INC currently manages clinical trials in 25 different countries withoffices in the U.S., Canada, Western Europe, and Eastern Europe.
Ken founded IHS (Integrated Healthcare Services), a healthcare service corporation that owned and managed outpatient primary care centers. IHS was sold to a major Healthcare Company, Catholic Healthcare West. Ken also founded NEUROPRACTICE, which sold subscriptions tonewsletters written for physicians in the neurology, neurosurgery and pain management fields. This company was sold to Wolters-Klower, the second largest publishing company in the world. Ken has extensive experience with in-licensing drugs/devices, development of marketing strategies, and new product launches.
Ken is a graduate of both the UCLA School of Medicine and Harvard Business School. He has advanced training/research in the neurosciences at both Vanderbilt Medical Center in Nashville, TN and the UCSD School of Medicine in San Diego. He is a licensed physician, board certified in both Pain Management and Neurology. He currently sits on the boards of the Harvard Business School Alumni Association and INC Research. In addition, Ken is a member of the Scientific Advisory Boards at the Institute for Aging, AlgoRx, and Photothera. He is an active member of YPO. Ken is considered an expert in the area of developing CNS/Pain drugs and devices in a global environment.
Apjohn Group Partners
Apjohn Ventures leverages over two hundred years of pharmaceutical experience from the fifteen Apjohn Group partners. For scientific expertise, the fund calls upon the medical, pharmacology, and chemistry expertise of the members with strong scientific and medical backgrounds. In addition to the PhDs and MDs, we leverage deep pharmaceutical expertise from several other partners experienced in marketing, finance and business development. Please visit Apjohn Group's website to learn more.